This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PDL BioPharma Enters Oversold Territory
by Zacks Equity Research
PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Why Is PDL BioPharma (PDLI) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.
Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
by Zacks Equity Research
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
by Zacks Equity Research
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
Axsome (AXSM) Completes Patient Randomization in TRD Study
by Zacks Equity Research
Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
by Zacks Equity Research
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
Catabasis (CATB) Partners with UK-Based Charity for DMD Study
by Zacks Equity Research
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
Why Is PDL BioPharma (PDLI) Up 5.3% Since Last Earnings Report?
by Zacks Equity Research
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales
by Zacks Equity Research
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
Why Is PDL BioPharma (PDLI) Down 20.1% Since Last Earnings Report?
by Zacks Equity Research
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
PDL BioPharma (PDLI) Down 9.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
by Zacks Equity Research
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
by Zacks Equity Research
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1
by Zacks Equity Research
Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.
Emergent (EBS) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.
Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1
by Zacks Equity Research
Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.
Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.
PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.
Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.
BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.